MTOR and cancer: RNF43 mutants with impaired E3 ligase function exhibit high dependency on the Wnt/FZD, PAR2, and the PI3K/mTOR signaling pathway, all of which are onco-targets affected by RNF43, as shown in Figure 4B. Therefore, the development of therapeutic drugs that effectively block these essential cancer targets is both timely and necessary.